nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.709	1	CiPCiCtD
Sirolimus—ABCB1—Vismodegib—skin cancer	0.022	0.159	CbGbCtD
Sirolimus—CYP3A4—Temozolomide—skin cancer	0.019	0.137	CbGbCtD
Sirolimus—CYP3A4—Imiquimod—skin cancer	0.019	0.137	CbGbCtD
Sirolimus—CYP3A4—Vismodegib—skin cancer	0.0132	0.0953	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0122	0.0883	CbGbCtD
Sirolimus—CYP3A7—Docetaxel—skin cancer	0.0122	0.0883	CbGbCtD
Sirolimus—ABCB1—Dactinomycin—skin cancer	0.0116	0.0835	CbGbCtD
Sirolimus—CYP3A4—Vemurafenib—skin cancer	0.0104	0.0753	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—skin cancer	0.00917	0.0663	CbGbCtD
Sirolimus—ABCB1—Docetaxel—skin cancer	0.00597	0.0431	CbGbCtD
Sirolimus—CYP3A4—Docetaxel—skin cancer	0.00358	0.0258	CbGbCtD
Sirolimus—MTOR—leg—skin cancer	0.003	0.0933	CbGeAlD
Sirolimus—MTOR—forelimb—skin cancer	0.00298	0.0926	CbGeAlD
Sirolimus—MTOR—hindlimb—skin cancer	0.00268	0.0833	CbGeAlD
Sirolimus—MTOR—appendage—skin cancer	0.0023	0.0715	CbGeAlD
Sirolimus—EIF4E—connective tissue—skin cancer	0.0017	0.0527	CbGeAlD
Sirolimus—MTOR—blood vessel—skin cancer	0.00128	0.0398	CbGeAlD
Sirolimus—EIF4E—lymphoid tissue—skin cancer	0.00124	0.0385	CbGeAlD
Sirolimus—EIF4E—female reproductive system—skin cancer	0.0012	0.0372	CbGeAlD
Sirolimus—EIF4E—head—skin cancer	0.000999	0.0311	CbGeAlD
Sirolimus—MTOR—neck—skin cancer	0.000915	0.0285	CbGeAlD
Sirolimus—FGF2—mammalian vulva—skin cancer	0.000851	0.0265	CbGeAlD
Sirolimus—FKBP1A—nipple—skin cancer	0.000832	0.0259	CbGeAlD
Sirolimus—FKBP1A—neck—skin cancer	0.000823	0.0256	CbGeAlD
Sirolimus—SLC47A1—nipple—skin cancer	0.000715	0.0222	CbGeAlD
Sirolimus—MTOR—connective tissue—skin cancer	0.000656	0.0204	CbGeAlD
Sirolimus—MTOR—epithelium—skin cancer	0.000623	0.0194	CbGeAlD
Sirolimus—MTOR—skin of body—skin cancer	0.000592	0.0184	CbGeAlD
Sirolimus—FKBP1A—connective tissue—skin cancer	0.00059	0.0183	CbGeAlD
Sirolimus—FKBP1A—epithelium—skin cancer	0.00056	0.0174	CbGeAlD
Sirolimus—MTOR—mammalian vulva—skin cancer	0.00054	0.0168	CbGeAlD
Sirolimus—FKBP1A—skin of body—skin cancer	0.000533	0.0166	CbGeAlD
Sirolimus—FKBP1A—mammalian vulva—skin cancer	0.000486	0.0151	CbGeAlD
Sirolimus—MTOR—lymphoid tissue—skin cancer	0.00048	0.0149	CbGeAlD
Sirolimus—MTOR—female reproductive system—skin cancer	0.000463	0.0144	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—skin cancer	0.000431	0.0134	CbGeAlD
Sirolimus—FGF2—lymph node—skin cancer	0.000426	0.0133	CbGeAlD
Sirolimus—SLC47A1—mammalian vulva—skin cancer	0.000417	0.013	CbGeAlD
Sirolimus—FKBP1A—female reproductive system—skin cancer	0.000416	0.0129	CbGeAlD
Sirolimus—MTOR—head—skin cancer	0.000386	0.012	CbGeAlD
Sirolimus—SLC47A1—female reproductive system—skin cancer	0.000358	0.0111	CbGeAlD
Sirolimus—SLCO1B1—female reproductive system—skin cancer	0.000353	0.011	CbGeAlD
Sirolimus—FKBP1A—head—skin cancer	0.000348	0.0108	CbGeAlD
Sirolimus—SLC47A1—head—skin cancer	0.000299	0.00929	CbGeAlD
Sirolimus—MTOR—lymph node—skin cancer	0.000271	0.00841	CbGeAlD
Sirolimus—ABCB1—blood vessel—skin cancer	0.000266	0.00828	CbGeAlD
Sirolimus—FKBP1A—lymph node—skin cancer	0.000243	0.00757	CbGeAlD
Sirolimus—SLC47A1—lymph node—skin cancer	0.000209	0.0065	CbGeAlD
Sirolimus—CYP3A4—female reproductive system—skin cancer	0.000136	0.00423	CbGeAlD
Sirolimus—ABCB1—epithelium—skin cancer	0.00013	0.00403	CbGeAlD
Sirolimus—ABCB1—mammalian vulva—skin cancer	0.000112	0.00349	CbGeAlD
Sirolimus—ABCB1—lymphoid tissue—skin cancer	9.98e-05	0.0031	CbGeAlD
Sirolimus—ABCB1—female reproductive system—skin cancer	9.62e-05	0.00299	CbGeAlD
Sirolimus—Sinusitis—Fluorouracil—skin cancer	9.03e-05	0.000995	CcSEcCtD
Sirolimus—Ill-defined disorder—Bleomycin—skin cancer	8.98e-05	0.000989	CcSEcCtD
Sirolimus—Anaemia—Bleomycin—skin cancer	8.94e-05	0.000985	CcSEcCtD
Sirolimus—Diarrhoea—Vemurafenib—skin cancer	8.92e-05	0.000982	CcSEcCtD
Sirolimus—Abdominal pain—Imiquimod—skin cancer	8.79e-05	0.000968	CcSEcCtD
Sirolimus—Body temperature increased—Imiquimod—skin cancer	8.79e-05	0.000968	CcSEcCtD
Sirolimus—Tinnitus—Temozolomide—skin cancer	8.74e-05	0.000963	CcSEcCtD
Sirolimus—Malaise—Bleomycin—skin cancer	8.73e-05	0.000961	CcSEcCtD
Sirolimus—Cardiac disorder—Temozolomide—skin cancer	8.7e-05	0.000959	CcSEcCtD
Sirolimus—Haemoglobin—Fluorouracil—skin cancer	8.68e-05	0.000956	CcSEcCtD
Sirolimus—Leukopenia—Bleomycin—skin cancer	8.66e-05	0.000954	CcSEcCtD
Sirolimus—Rhinitis—Fluorouracil—skin cancer	8.66e-05	0.000954	CcSEcCtD
Sirolimus—Haemorrhage—Fluorouracil—skin cancer	8.64e-05	0.000952	CcSEcCtD
Sirolimus—Dizziness—Vemurafenib—skin cancer	8.62e-05	0.000949	CcSEcCtD
Sirolimus—Hypoaesthesia—Fluorouracil—skin cancer	8.59e-05	0.000947	CcSEcCtD
Sirolimus—Pharyngitis—Fluorouracil—skin cancer	8.57e-05	0.000944	CcSEcCtD
Sirolimus—Angiopathy—Temozolomide—skin cancer	8.51e-05	0.000937	CcSEcCtD
Sirolimus—Immune system disorder—Temozolomide—skin cancer	8.47e-05	0.000933	CcSEcCtD
Sirolimus—Mediastinal disorder—Temozolomide—skin cancer	8.45e-05	0.000931	CcSEcCtD
Sirolimus—Cough—Bleomycin—skin cancer	8.44e-05	0.00093	CcSEcCtD
Sirolimus—Chills—Temozolomide—skin cancer	8.41e-05	0.000927	CcSEcCtD
Sirolimus—Dehydration—Docetaxel—skin cancer	8.38e-05	0.000923	CcSEcCtD
Sirolimus—Ill-defined disorder—Dactinomycin—skin cancer	8.37e-05	0.000922	CcSEcCtD
Sirolimus—Anaemia—Dactinomycin—skin cancer	8.34e-05	0.000919	CcSEcCtD
Sirolimus—Liver function test abnormal—Docetaxel—skin cancer	8.32e-05	0.000917	CcSEcCtD
Sirolimus—Vomiting—Vemurafenib—skin cancer	8.29e-05	0.000913	CcSEcCtD
Sirolimus—Chest pain—Bleomycin—skin cancer	8.24e-05	0.000907	CcSEcCtD
Sirolimus—Myalgia—Bleomycin—skin cancer	8.24e-05	0.000907	CcSEcCtD
Sirolimus—Orthostatic hypotension—Docetaxel—skin cancer	8.23e-05	0.000907	CcSEcCtD
Sirolimus—Rash—Vemurafenib—skin cancer	8.22e-05	0.000905	CcSEcCtD
Sirolimus—Dermatitis—Vemurafenib—skin cancer	8.21e-05	0.000904	CcSEcCtD
Sirolimus—Hypersensitivity—Imiquimod—skin cancer	8.19e-05	0.000902	CcSEcCtD
Sirolimus—Headache—Vemurafenib—skin cancer	8.16e-05	0.000899	CcSEcCtD
Sirolimus—Malnutrition—Temozolomide—skin cancer	8.16e-05	0.000899	CcSEcCtD
Sirolimus—Breast disorder—Docetaxel—skin cancer	8.14e-05	0.000897	CcSEcCtD
Sirolimus—Discomfort—Bleomycin—skin cancer	8.14e-05	0.000897	CcSEcCtD
Sirolimus—Malaise—Dactinomycin—skin cancer	8.14e-05	0.000896	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Docetaxel—skin cancer	8.12e-05	0.000894	CcSEcCtD
Sirolimus—Leukopenia—Dactinomycin—skin cancer	8.08e-05	0.00089	CcSEcCtD
Sirolimus—ABCB1—head—skin cancer	8.04e-05	0.0025	CbGeAlD
Sirolimus—Asthenia—Imiquimod—skin cancer	7.97e-05	0.000879	CcSEcCtD
Sirolimus—Confusional state—Bleomycin—skin cancer	7.96e-05	0.000877	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Docetaxel—skin cancer	7.95e-05	0.000876	CcSEcCtD
Sirolimus—Oedema—Bleomycin—skin cancer	7.9e-05	0.00087	CcSEcCtD
Sirolimus—Anaphylactic shock—Bleomycin—skin cancer	7.9e-05	0.00087	CcSEcCtD
Sirolimus—Back pain—Temozolomide—skin cancer	7.89e-05	0.00087	CcSEcCtD
Sirolimus—Pruritus—Imiquimod—skin cancer	7.86e-05	0.000866	CcSEcCtD
Sirolimus—Infection—Bleomycin—skin cancer	7.84e-05	0.000864	CcSEcCtD
Sirolimus—Dysphagia—Docetaxel—skin cancer	7.79e-05	0.000858	CcSEcCtD
Sirolimus—Nausea—Vemurafenib—skin cancer	7.74e-05	0.000853	CcSEcCtD
Sirolimus—Thrombocytopenia—Bleomycin—skin cancer	7.73e-05	0.000852	CcSEcCtD
Sirolimus—Myalgia—Dactinomycin—skin cancer	7.68e-05	0.000846	CcSEcCtD
Sirolimus—Tremor—Temozolomide—skin cancer	7.65e-05	0.000842	CcSEcCtD
Sirolimus—Diarrhoea—Imiquimod—skin cancer	7.6e-05	0.000838	CcSEcCtD
Sirolimus—Discomfort—Dactinomycin—skin cancer	7.59e-05	0.000836	CcSEcCtD
Sirolimus—Ill-defined disorder—Temozolomide—skin cancer	7.57e-05	0.000834	CcSEcCtD
Sirolimus—Anaemia—Temozolomide—skin cancer	7.54e-05	0.000831	CcSEcCtD
Sirolimus—Anorexia—Bleomycin—skin cancer	7.53e-05	0.000829	CcSEcCtD
Sirolimus—Agitation—Temozolomide—skin cancer	7.5e-05	0.000826	CcSEcCtD
Sirolimus—Angioedema—Temozolomide—skin cancer	7.46e-05	0.000822	CcSEcCtD
Sirolimus—Pancytopenia—Docetaxel—skin cancer	7.4e-05	0.000815	CcSEcCtD
Sirolimus—Hypotension—Bleomycin—skin cancer	7.38e-05	0.000813	CcSEcCtD
Sirolimus—Oedema—Dactinomycin—skin cancer	7.36e-05	0.000811	CcSEcCtD
Sirolimus—Malaise—Temozolomide—skin cancer	7.36e-05	0.000811	CcSEcCtD
Sirolimus—Dizziness—Imiquimod—skin cancer	7.35e-05	0.00081	CcSEcCtD
Sirolimus—Infection—Dactinomycin—skin cancer	7.32e-05	0.000806	CcSEcCtD
Sirolimus—Leukopenia—Temozolomide—skin cancer	7.31e-05	0.000805	CcSEcCtD
Sirolimus—Neutropenia—Docetaxel—skin cancer	7.28e-05	0.000802	CcSEcCtD
Sirolimus—Palpitations—Temozolomide—skin cancer	7.21e-05	0.000795	CcSEcCtD
Sirolimus—Thrombocytopenia—Dactinomycin—skin cancer	7.21e-05	0.000794	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Bleomycin—skin cancer	7.19e-05	0.000793	CcSEcCtD
Sirolimus—Cough—Temozolomide—skin cancer	7.12e-05	0.000785	CcSEcCtD
Sirolimus—Paraesthesia—Bleomycin—skin cancer	7.09e-05	0.000781	CcSEcCtD
Sirolimus—Weight increased—Docetaxel—skin cancer	7.09e-05	0.000781	CcSEcCtD
Sirolimus—Vomiting—Imiquimod—skin cancer	7.07e-05	0.000779	CcSEcCtD
Sirolimus—Weight decreased—Docetaxel—skin cancer	7.05e-05	0.000776	CcSEcCtD
Sirolimus—Hypertension—Temozolomide—skin cancer	7.05e-05	0.000776	CcSEcCtD
Sirolimus—Dyspnoea—Bleomycin—skin cancer	7.04e-05	0.000776	CcSEcCtD
Sirolimus—Anorexia—Dactinomycin—skin cancer	7.02e-05	0.000773	CcSEcCtD
Sirolimus—Rash—Imiquimod—skin cancer	7.01e-05	0.000772	CcSEcCtD
Sirolimus—Dermatitis—Imiquimod—skin cancer	7e-05	0.000771	CcSEcCtD
Sirolimus—Pneumonia—Docetaxel—skin cancer	6.99e-05	0.00077	CcSEcCtD
Sirolimus—Headache—Imiquimod—skin cancer	6.96e-05	0.000767	CcSEcCtD
Sirolimus—Anaemia—Fluorouracil—skin cancer	6.95e-05	0.000766	CcSEcCtD
Sirolimus—Myalgia—Temozolomide—skin cancer	6.95e-05	0.000765	CcSEcCtD
Sirolimus—Arthralgia—Temozolomide—skin cancer	6.95e-05	0.000765	CcSEcCtD
Sirolimus—Infestation NOS—Docetaxel—skin cancer	6.95e-05	0.000765	CcSEcCtD
Sirolimus—Infestation—Docetaxel—skin cancer	6.95e-05	0.000765	CcSEcCtD
Sirolimus—Anxiety—Temozolomide—skin cancer	6.92e-05	0.000763	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	6.9e-05	0.00076	CcSEcCtD
Sirolimus—Discomfort—Temozolomide—skin cancer	6.87e-05	0.000756	CcSEcCtD
Sirolimus—Decreased appetite—Bleomycin—skin cancer	6.86e-05	0.000756	CcSEcCtD
Sirolimus—Neuropathy peripheral—Docetaxel—skin cancer	6.81e-05	0.00075	CcSEcCtD
Sirolimus—Stomatitis—Docetaxel—skin cancer	6.77e-05	0.000746	CcSEcCtD
Sirolimus—Pain—Bleomycin—skin cancer	6.75e-05	0.000744	CcSEcCtD
Sirolimus—Conjunctivitis—Docetaxel—skin cancer	6.75e-05	0.000744	CcSEcCtD
Sirolimus—Leukopenia—Fluorouracil—skin cancer	6.73e-05	0.000742	CcSEcCtD
Sirolimus—Confusional state—Temozolomide—skin cancer	6.72e-05	0.00074	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Dactinomycin—skin cancer	6.71e-05	0.000739	CcSEcCtD
Sirolimus—Anaphylactic shock—Temozolomide—skin cancer	6.66e-05	0.000734	CcSEcCtD
Sirolimus—Oedema—Temozolomide—skin cancer	6.66e-05	0.000734	CcSEcCtD
Sirolimus—Infection—Temozolomide—skin cancer	6.62e-05	0.000729	CcSEcCtD
Sirolimus—Nausea—Imiquimod—skin cancer	6.6e-05	0.000727	CcSEcCtD
Sirolimus—Hepatobiliary disease—Docetaxel—skin cancer	6.57e-05	0.000724	CcSEcCtD
Sirolimus—Epistaxis—Docetaxel—skin cancer	6.55e-05	0.000722	CcSEcCtD
Sirolimus—Nervous system disorder—Temozolomide—skin cancer	6.53e-05	0.00072	CcSEcCtD
Sirolimus—Thrombocytopenia—Temozolomide—skin cancer	6.52e-05	0.000718	CcSEcCtD
Sirolimus—Feeling abnormal—Bleomycin—skin cancer	6.51e-05	0.000717	CcSEcCtD
Sirolimus—Skin disorder—Temozolomide—skin cancer	6.47e-05	0.000713	CcSEcCtD
Sirolimus—Hyperhidrosis—Temozolomide—skin cancer	6.44e-05	0.000709	CcSEcCtD
Sirolimus—Myalgia—Fluorouracil—skin cancer	6.4e-05	0.000705	CcSEcCtD
Sirolimus—Chest pain—Fluorouracil—skin cancer	6.4e-05	0.000705	CcSEcCtD
Sirolimus—Decreased appetite—Dactinomycin—skin cancer	6.4e-05	0.000705	CcSEcCtD
Sirolimus—Anorexia—Temozolomide—skin cancer	6.35e-05	0.000699	CcSEcCtD
Sirolimus—Discomfort—Fluorouracil—skin cancer	6.33e-05	0.000697	CcSEcCtD
Sirolimus—Pain—Dactinomycin—skin cancer	6.3e-05	0.000694	CcSEcCtD
Sirolimus—Haemoglobin—Docetaxel—skin cancer	6.27e-05	0.00069	CcSEcCtD
Sirolimus—Rhinitis—Docetaxel—skin cancer	6.25e-05	0.000689	CcSEcCtD
Sirolimus—Body temperature increased—Bleomycin—skin cancer	6.24e-05	0.000688	CcSEcCtD
Sirolimus—Haemorrhage—Docetaxel—skin cancer	6.23e-05	0.000687	CcSEcCtD
Sirolimus—Hypoaesthesia—Docetaxel—skin cancer	6.2e-05	0.000683	CcSEcCtD
Sirolimus—Confusional state—Fluorouracil—skin cancer	6.19e-05	0.000682	CcSEcCtD
Sirolimus—Pharyngitis—Docetaxel—skin cancer	6.19e-05	0.000682	CcSEcCtD
Sirolimus—Urinary tract disorder—Docetaxel—skin cancer	6.16e-05	0.000678	CcSEcCtD
Sirolimus—Oedema peripheral—Docetaxel—skin cancer	6.14e-05	0.000677	CcSEcCtD
Sirolimus—Oedema—Fluorouracil—skin cancer	6.14e-05	0.000676	CcSEcCtD
Sirolimus—Anaphylactic shock—Fluorouracil—skin cancer	6.14e-05	0.000676	CcSEcCtD
Sirolimus—Connective tissue disorder—Docetaxel—skin cancer	6.13e-05	0.000675	CcSEcCtD
Sirolimus—Urethral disorder—Docetaxel—skin cancer	6.11e-05	0.000673	CcSEcCtD
Sirolimus—Infection—Fluorouracil—skin cancer	6.1e-05	0.000672	CcSEcCtD
Sirolimus—Feeling abnormal—Dactinomycin—skin cancer	6.07e-05	0.000669	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Temozolomide—skin cancer	6.07e-05	0.000669	CcSEcCtD
Sirolimus—Insomnia—Temozolomide—skin cancer	6.02e-05	0.000664	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dactinomycin—skin cancer	6.02e-05	0.000663	CcSEcCtD
Sirolimus—Nervous system disorder—Fluorouracil—skin cancer	6.02e-05	0.000663	CcSEcCtD
Sirolimus—Thrombocytopenia—Fluorouracil—skin cancer	6.01e-05	0.000662	CcSEcCtD
Sirolimus—Visual impairment—Docetaxel—skin cancer	6.01e-05	0.000662	CcSEcCtD
Sirolimus—Tachycardia—Fluorouracil—skin cancer	5.99e-05	0.00066	CcSEcCtD
Sirolimus—Paraesthesia—Temozolomide—skin cancer	5.98e-05	0.000659	CcSEcCtD
Sirolimus—Dyspnoea—Temozolomide—skin cancer	5.94e-05	0.000654	CcSEcCtD
Sirolimus—Somnolence—Temozolomide—skin cancer	5.92e-05	0.000652	CcSEcCtD
Sirolimus—Dyspepsia—Temozolomide—skin cancer	5.86e-05	0.000646	CcSEcCtD
Sirolimus—Anorexia—Fluorouracil—skin cancer	5.85e-05	0.000644	CcSEcCtD
Sirolimus—Abdominal pain—Dactinomycin—skin cancer	5.82e-05	0.000641	CcSEcCtD
Sirolimus—Body temperature increased—Dactinomycin—skin cancer	5.82e-05	0.000641	CcSEcCtD
Sirolimus—Hypersensitivity—Bleomycin—skin cancer	5.82e-05	0.000641	CcSEcCtD
Sirolimus—Decreased appetite—Temozolomide—skin cancer	5.79e-05	0.000638	CcSEcCtD
Sirolimus—Cardiac disorder—Docetaxel—skin cancer	5.79e-05	0.000637	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Temozolomide—skin cancer	5.75e-05	0.000633	CcSEcCtD
Sirolimus—Hypotension—Fluorouracil—skin cancer	5.73e-05	0.000632	CcSEcCtD
Sirolimus—Pain—Temozolomide—skin cancer	5.7e-05	0.000627	CcSEcCtD
Sirolimus—Constipation—Temozolomide—skin cancer	5.7e-05	0.000627	CcSEcCtD
Sirolimus—Asthenia—Bleomycin—skin cancer	5.67e-05	0.000624	CcSEcCtD
Sirolimus—Angiopathy—Docetaxel—skin cancer	5.66e-05	0.000623	CcSEcCtD
Sirolimus—Immune system disorder—Docetaxel—skin cancer	5.63e-05	0.00062	CcSEcCtD
Sirolimus—ABCB1—lymph node—skin cancer	5.63e-05	0.00175	CbGeAlD
Sirolimus—Mediastinal disorder—Docetaxel—skin cancer	5.62e-05	0.000619	CcSEcCtD
Sirolimus—Chills—Docetaxel—skin cancer	5.59e-05	0.000616	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Fluorouracil—skin cancer	5.59e-05	0.000616	CcSEcCtD
Sirolimus—Pruritus—Bleomycin—skin cancer	5.59e-05	0.000615	CcSEcCtD
Sirolimus—Insomnia—Fluorouracil—skin cancer	5.55e-05	0.000611	CcSEcCtD
Sirolimus—Paraesthesia—Fluorouracil—skin cancer	5.51e-05	0.000607	CcSEcCtD
Sirolimus—Feeling abnormal—Temozolomide—skin cancer	5.49e-05	0.000605	CcSEcCtD
Sirolimus—Dyspnoea—Fluorouracil—skin cancer	5.47e-05	0.000603	CcSEcCtD
Sirolimus—Somnolence—Fluorouracil—skin cancer	5.46e-05	0.000601	CcSEcCtD
Sirolimus—Gastrointestinal pain—Temozolomide—skin cancer	5.45e-05	0.0006	CcSEcCtD
Sirolimus—Malnutrition—Docetaxel—skin cancer	5.43e-05	0.000598	CcSEcCtD
Sirolimus—Hypersensitivity—Dactinomycin—skin cancer	5.43e-05	0.000598	CcSEcCtD
Sirolimus—Dyspepsia—Fluorouracil—skin cancer	5.4e-05	0.000595	CcSEcCtD
Sirolimus—Decreased appetite—Fluorouracil—skin cancer	5.33e-05	0.000588	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Fluorouracil—skin cancer	5.3e-05	0.000584	CcSEcCtD
Sirolimus—Asthenia—Dactinomycin—skin cancer	5.28e-05	0.000582	CcSEcCtD
Sirolimus—Abdominal pain—Temozolomide—skin cancer	5.27e-05	0.00058	CcSEcCtD
Sirolimus—Body temperature increased—Temozolomide—skin cancer	5.27e-05	0.00058	CcSEcCtD
Sirolimus—Back pain—Docetaxel—skin cancer	5.25e-05	0.000578	CcSEcCtD
Sirolimus—Pain—Fluorouracil—skin cancer	5.25e-05	0.000578	CcSEcCtD
Sirolimus—Muscle spasms—Docetaxel—skin cancer	5.22e-05	0.000575	CcSEcCtD
Sirolimus—Feeling abnormal—Fluorouracil—skin cancer	5.06e-05	0.000557	CcSEcCtD
Sirolimus—Diarrhoea—Dactinomycin—skin cancer	5.04e-05	0.000555	CcSEcCtD
Sirolimus—Vomiting—Bleomycin—skin cancer	5.02e-05	0.000553	CcSEcCtD
Sirolimus—Anaemia—Docetaxel—skin cancer	5.02e-05	0.000553	CcSEcCtD
Sirolimus—Rash—Bleomycin—skin cancer	4.98e-05	0.000548	CcSEcCtD
Sirolimus—Dermatitis—Bleomycin—skin cancer	4.97e-05	0.000548	CcSEcCtD
Sirolimus—Hypersensitivity—Temozolomide—skin cancer	4.91e-05	0.000541	CcSEcCtD
Sirolimus—Syncope—Docetaxel—skin cancer	4.87e-05	0.000536	CcSEcCtD
Sirolimus—Leukopenia—Docetaxel—skin cancer	4.86e-05	0.000535	CcSEcCtD
Sirolimus—Body temperature increased—Fluorouracil—skin cancer	4.85e-05	0.000534	CcSEcCtD
Sirolimus—Palpitations—Docetaxel—skin cancer	4.8e-05	0.000528	CcSEcCtD
Sirolimus—Asthenia—Temozolomide—skin cancer	4.78e-05	0.000526	CcSEcCtD
Sirolimus—Loss of consciousness—Docetaxel—skin cancer	4.77e-05	0.000526	CcSEcCtD
Sirolimus—Cough—Docetaxel—skin cancer	4.74e-05	0.000522	CcSEcCtD
Sirolimus—Pruritus—Temozolomide—skin cancer	4.71e-05	0.000519	CcSEcCtD
Sirolimus—Nausea—Bleomycin—skin cancer	4.69e-05	0.000517	CcSEcCtD
Sirolimus—Hypertension—Docetaxel—skin cancer	4.69e-05	0.000516	CcSEcCtD
Sirolimus—Vomiting—Dactinomycin—skin cancer	4.68e-05	0.000516	CcSEcCtD
Sirolimus—Rash—Dactinomycin—skin cancer	4.64e-05	0.000512	CcSEcCtD
Sirolimus—Chest pain—Docetaxel—skin cancer	4.62e-05	0.000509	CcSEcCtD
Sirolimus—Arthralgia—Docetaxel—skin cancer	4.62e-05	0.000509	CcSEcCtD
Sirolimus—Myalgia—Docetaxel—skin cancer	4.62e-05	0.000509	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	4.59e-05	0.000506	CcSEcCtD
Sirolimus—Diarrhoea—Temozolomide—skin cancer	4.56e-05	0.000502	CcSEcCtD
Sirolimus—Hypersensitivity—Fluorouracil—skin cancer	4.52e-05	0.000498	CcSEcCtD
Sirolimus—Confusional state—Docetaxel—skin cancer	4.47e-05	0.000492	CcSEcCtD
Sirolimus—Anaphylactic shock—Docetaxel—skin cancer	4.43e-05	0.000488	CcSEcCtD
Sirolimus—Oedema—Docetaxel—skin cancer	4.43e-05	0.000488	CcSEcCtD
Sirolimus—Dizziness—Temozolomide—skin cancer	4.4e-05	0.000485	CcSEcCtD
Sirolimus—Infection—Docetaxel—skin cancer	4.4e-05	0.000485	CcSEcCtD
Sirolimus—Nausea—Dactinomycin—skin cancer	4.37e-05	0.000482	CcSEcCtD
Sirolimus—Shock—Docetaxel—skin cancer	4.36e-05	0.00048	CcSEcCtD
Sirolimus—Nervous system disorder—Docetaxel—skin cancer	4.34e-05	0.000479	CcSEcCtD
Sirolimus—Pruritus—Fluorouracil—skin cancer	4.34e-05	0.000478	CcSEcCtD
Sirolimus—Thrombocytopenia—Docetaxel—skin cancer	4.34e-05	0.000478	CcSEcCtD
Sirolimus—Tachycardia—Docetaxel—skin cancer	4.32e-05	0.000476	CcSEcCtD
Sirolimus—Skin disorder—Docetaxel—skin cancer	4.3e-05	0.000474	CcSEcCtD
Sirolimus—Vomiting—Temozolomide—skin cancer	4.24e-05	0.000467	CcSEcCtD
Sirolimus—Anorexia—Docetaxel—skin cancer	4.22e-05	0.000465	CcSEcCtD
Sirolimus—Rash—Temozolomide—skin cancer	4.2e-05	0.000463	CcSEcCtD
Sirolimus—Diarrhoea—Fluorouracil—skin cancer	4.2e-05	0.000463	CcSEcCtD
Sirolimus—Dermatitis—Temozolomide—skin cancer	4.2e-05	0.000462	CcSEcCtD
Sirolimus—Headache—Temozolomide—skin cancer	4.17e-05	0.00046	CcSEcCtD
Sirolimus—Hypotension—Docetaxel—skin cancer	4.14e-05	0.000456	CcSEcCtD
Sirolimus—Dizziness—Fluorouracil—skin cancer	4.06e-05	0.000447	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—skin cancer	4.04e-05	0.000445	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—skin cancer	4.01e-05	0.000441	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—skin cancer	3.98e-05	0.000438	CcSEcCtD
Sirolimus—Nausea—Temozolomide—skin cancer	3.96e-05	0.000436	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—skin cancer	3.95e-05	0.000435	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—skin cancer	3.94e-05	0.000434	CcSEcCtD
Sirolimus—Vomiting—Fluorouracil—skin cancer	3.9e-05	0.00043	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—skin cancer	3.9e-05	0.00043	CcSEcCtD
Sirolimus—Rash—Fluorouracil—skin cancer	3.87e-05	0.000426	CcSEcCtD
Sirolimus—Dermatitis—Fluorouracil—skin cancer	3.87e-05	0.000426	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—skin cancer	3.85e-05	0.000424	CcSEcCtD
Sirolimus—Headache—Fluorouracil—skin cancer	3.84e-05	0.000424	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—skin cancer	3.82e-05	0.000421	CcSEcCtD
Sirolimus—Pain—Docetaxel—skin cancer	3.79e-05	0.000417	CcSEcCtD
Sirolimus—Constipation—Docetaxel—skin cancer	3.79e-05	0.000417	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—skin cancer	3.65e-05	0.000402	CcSEcCtD
Sirolimus—Nausea—Fluorouracil—skin cancer	3.65e-05	0.000402	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—skin cancer	3.62e-05	0.000399	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—skin cancer	3.5e-05	0.000386	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—skin cancer	3.5e-05	0.000386	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—skin cancer	3.26e-05	0.00036	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—skin cancer	3.18e-05	0.00035	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—skin cancer	3.13e-05	0.000345	CcSEcCtD
Sirolimus—Diarrhoea—Docetaxel—skin cancer	3.03e-05	0.000334	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—skin cancer	2.93e-05	0.000323	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—skin cancer	2.82e-05	0.00031	CcSEcCtD
Sirolimus—Rash—Docetaxel—skin cancer	2.79e-05	0.000308	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—skin cancer	2.79e-05	0.000307	CcSEcCtD
Sirolimus—Headache—Docetaxel—skin cancer	2.77e-05	0.000306	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—NRAS—skin cancer	2.76e-05	0.000921	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—HRAS—skin cancer	2.74e-05	0.000917	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—HRAS—skin cancer	2.73e-05	0.000912	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTCH2—skin cancer	2.72e-05	0.000908	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—HRAS—skin cancer	2.72e-05	0.000908	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	2.72e-05	0.000908	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—skin cancer	2.72e-05	0.000907	CbGpPWpGaD
Sirolimus—FGF2—Disease—ENO2—skin cancer	2.69e-05	0.0009	CbGpPWpGaD
Sirolimus—FGF2—Disease—SHH—skin cancer	2.69e-05	0.0009	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—HRAS—skin cancer	2.68e-05	0.000895	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	2.68e-05	0.000895	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—KRAS—skin cancer	2.68e-05	0.000894	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	2.66e-05	0.00089	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.66e-05	0.00089	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—HRAS—skin cancer	2.66e-05	0.000889	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MC1R—skin cancer	2.65e-05	0.000885	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—IL6—skin cancer	2.64e-05	0.000882	CbGpPWpGaD
Sirolimus—Nausea—Docetaxel—skin cancer	2.63e-05	0.00029	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—PLIN2—skin cancer	2.63e-05	0.000878	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—IL6—skin cancer	2.63e-05	0.000877	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—IL6—skin cancer	2.61e-05	0.000873	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GLI1—skin cancer	2.61e-05	0.000872	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—IL6—skin cancer	2.6e-05	0.000869	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—NRAS—skin cancer	2.59e-05	0.000866	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—NRAS—skin cancer	2.59e-05	0.000866	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	2.59e-05	0.000866	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CDKN2A—skin cancer	2.59e-05	0.000865	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—NRAS—skin cancer	2.57e-05	0.000859	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—IL6—skin cancer	2.56e-05	0.000857	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—skin cancer	2.56e-05	0.000856	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—HRAS—skin cancer	2.56e-05	0.000854	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HRAS—skin cancer	2.56e-05	0.000854	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	2.56e-05	0.000854	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—skin cancer	2.55e-05	0.000851	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—IL6—skin cancer	2.55e-05	0.000851	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—NRAS—skin cancer	2.54e-05	0.000847	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—skin cancer	2.53e-05	0.000847	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—HRAS—skin cancer	2.53e-05	0.000846	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—KRAS—skin cancer	2.52e-05	0.000842	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.51e-05	0.00084	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—HRAS—skin cancer	2.51e-05	0.000839	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—HRAS—skin cancer	2.5e-05	0.000835	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SHH—skin cancer	2.49e-05	0.000832	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SUFU—skin cancer	2.47e-05	0.000826	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RASA1—skin cancer	2.47e-05	0.000826	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—IL6—skin cancer	2.45e-05	0.000817	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	2.45e-05	0.000817	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—IL6—skin cancer	2.45e-05	0.000817	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—IL6—skin cancer	2.42e-05	0.00081	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PLIN2—skin cancer	2.41e-05	0.000806	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—KRAS—skin cancer	2.41e-05	0.000804	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—IL6—skin cancer	2.4e-05	0.000803	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—NRAS—skin cancer	2.4e-05	0.000802	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—KRAS—skin cancer	2.4e-05	0.0008	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	2.4e-05	0.0008	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—IL6—skin cancer	2.39e-05	0.000799	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—KRAS—skin cancer	2.38e-05	0.000796	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—NRAS—skin cancer	2.38e-05	0.000795	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FOXO4—skin cancer	2.38e-05	0.000795	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—KRAS—skin cancer	2.37e-05	0.000793	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—HRAS—skin cancer	2.37e-05	0.00079	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTCH1—skin cancer	2.36e-05	0.000788	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SMO—skin cancer	2.36e-05	0.000788	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	2.34e-05	0.000781	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTGER4—skin cancer	2.3e-05	0.000768	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	2.3e-05	0.000767	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—HRAS—skin cancer	2.28e-05	0.00076	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	2.26e-05	0.000756	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—skin cancer	2.25e-05	0.000753	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—HRAS—skin cancer	2.24e-05	0.000748	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	2.23e-05	0.000746	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—KRAS—skin cancer	2.23e-05	0.000746	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—KRAS—skin cancer	2.23e-05	0.000746	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—KRAS—skin cancer	2.21e-05	0.000739	CbGpPWpGaD
Sirolimus—FGF2—Disease—FOXO4—skin cancer	2.2e-05	0.000734	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—skin cancer	2.19e-05	0.000732	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—KRAS—skin cancer	2.18e-05	0.000729	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—IL6—skin cancer	2.18e-05	0.000728	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—skin cancer	2.18e-05	0.000727	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	2.17e-05	0.000724	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—HRAS—skin cancer	2.14e-05	0.000716	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CSPG4—skin cancer	2.12e-05	0.000708	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—IL6—skin cancer	2.08e-05	0.000696	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—KRAS—skin cancer	2.07e-05	0.00069	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERCC2—skin cancer	2.06e-05	0.00069	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GLI2—skin cancer	2.06e-05	0.000688	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—HRAS—skin cancer	2.06e-05	0.000687	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—IL6—skin cancer	2.05e-05	0.000685	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—KRAS—skin cancer	2.05e-05	0.000684	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—HRAS—skin cancer	2.05e-05	0.000684	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—HRAS—skin cancer	2.04e-05	0.00068	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	2.04e-05	0.00068	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FOXO4—skin cancer	2.03e-05	0.000678	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—HRAS—skin cancer	2.03e-05	0.000677	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—HRAS—skin cancer	2.02e-05	0.000674	CbGpPWpGaD
Sirolimus—MTOR—Disease—SHH—skin cancer	2e-05	0.000668	CbGpPWpGaD
Sirolimus—MTOR—Disease—ENO2—skin cancer	2e-05	0.000668	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	1.99e-05	0.000664	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.98e-05	0.00066	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MC1R—skin cancer	1.96e-05	0.000656	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—IL6—skin cancer	1.96e-05	0.000654	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—skin cancer	1.95e-05	0.000651	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CSPG4—skin cancer	1.94e-05	0.00065	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—skin cancer	1.94e-05	0.000648	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GLI1—skin cancer	1.94e-05	0.000647	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TERT—skin cancer	1.94e-05	0.000647	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—skin cancer	1.93e-05	0.000645	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HRAS—skin cancer	1.9e-05	0.000634	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—HRAS—skin cancer	1.9e-05	0.000634	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.9e-05	0.000634	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.89e-05	0.000631	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SHH—skin cancer	1.89e-05	0.00063	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—HRAS—skin cancer	1.88e-05	0.000628	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RASA1—skin cancer	1.87e-05	0.000626	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—skin cancer	1.86e-05	0.000623	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—HRAS—skin cancer	1.86e-05	0.00062	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TERT—skin cancer	1.85e-05	0.000617	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SUFU—skin cancer	1.84e-05	0.000613	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—skin cancer	1.82e-05	0.000607	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.82e-05	0.000607	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—skin cancer	1.82e-05	0.000607	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—skin cancer	1.8e-05	0.000601	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTCH1—skin cancer	1.79e-05	0.000598	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SMO—skin cancer	1.79e-05	0.000598	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—skin cancer	1.78e-05	0.000596	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—skin cancer	1.78e-05	0.000593	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NRAS—skin cancer	1.77e-05	0.00059	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FOXO4—skin cancer	1.77e-05	0.00059	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—HRAS—skin cancer	1.76e-05	0.000587	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PLIN2—skin cancer	1.74e-05	0.000582	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—HRAS—skin cancer	1.74e-05	0.000582	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTGER4—skin cancer	1.74e-05	0.000582	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.68e-05	0.000561	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—skin cancer	1.67e-05	0.000557	CbGpPWpGaD
Sirolimus—MTOR—Disease—FOXO4—skin cancer	1.63e-05	0.000545	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.61e-05	0.000537	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERCC2—skin cancer	1.56e-05	0.000523	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FOXO4—skin cancer	1.54e-05	0.000514	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NRAS—skin cancer	1.54e-05	0.000514	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—BRAF—skin cancer	1.53e-05	0.000512	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—KRAS—skin cancer	1.52e-05	0.000508	CbGpPWpGaD
Sirolimus—FGF2—Disease—TERT—skin cancer	1.47e-05	0.00049	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—BRAF—skin cancer	1.46e-05	0.000489	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—skin cancer	1.44e-05	0.000481	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO2—skin cancer	1.44e-05	0.000481	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—skin cancer	1.42e-05	0.000475	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CSPG4—skin cancer	1.41e-05	0.00047	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SHH—skin cancer	1.4e-05	0.000468	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RASA1—skin cancer	1.39e-05	0.000465	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—skin cancer	1.36e-05	0.000454	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TERT—skin cancer	1.36e-05	0.000453	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.35e-05	0.000451	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTCH1—skin cancer	1.33e-05	0.000443	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMO—skin cancer	1.33e-05	0.000443	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—skin cancer	1.32e-05	0.000442	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO2—skin cancer	1.32e-05	0.000442	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—skin cancer	1.32e-05	0.000441	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLIN2—skin cancer	1.32e-05	0.00044	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—skin cancer	1.3e-05	0.000436	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—skin cancer	1.29e-05	0.000432	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTGER4—skin cancer	1.29e-05	0.000432	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—skin cancer	1.24e-05	0.000414	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—skin cancer	1.24e-05	0.000413	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—skin cancer	1.22e-05	0.000409	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—skin cancer	1.17e-05	0.00039	CbGpPWpGaD
Sirolimus—FGF2—Disease—BRAF—skin cancer	1.16e-05	0.000388	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERCC2—skin cancer	1.16e-05	0.000388	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FOXO4—skin cancer	1.14e-05	0.000381	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.13e-05	0.000376	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—skin cancer	1.12e-05	0.000376	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—skin cancer	1.12e-05	0.000375	CbGpPWpGaD
Sirolimus—MTOR—Disease—TERT—skin cancer	1.09e-05	0.000364	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—skin cancer	1.08e-05	0.00036	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BRAF—skin cancer	1.07e-05	0.000359	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CSPG4—skin cancer	1.06e-05	0.000354	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—skin cancer	1.04e-05	0.000348	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TERT—skin cancer	1.03e-05	0.000343	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—skin cancer	1.01e-05	0.000337	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—skin cancer	9.96e-06	0.000333	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—skin cancer	9.93e-06	0.000332	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—skin cancer	9.67e-06	0.000323	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—skin cancer	9.63e-06	0.000322	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—skin cancer	9.55e-06	0.000319	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—skin cancer	9.54e-06	0.000319	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—skin cancer	9.51e-06	0.000318	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—skin cancer	9.38e-06	0.000313	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—skin cancer	9.2e-06	0.000307	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.04e-06	0.000302	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—skin cancer	8.67e-06	0.00029	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—skin cancer	8.62e-06	0.000288	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ERCC2—skin cancer	8.36e-06	0.000279	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—skin cancer	8.33e-06	0.000278	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—skin cancer	8.29e-06	0.000277	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—skin cancer	8.13e-06	0.000272	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLIN2—skin cancer	8.11e-06	0.000271	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.03e-06	0.000268	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—skin cancer	7.92e-06	0.000264	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—skin cancer	7.91e-06	0.000264	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ERCC2—skin cancer	7.68e-06	0.000256	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—skin cancer	7.62e-06	0.000255	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—skin cancer	7.37e-06	0.000246	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—skin cancer	7.3e-06	0.000244	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—skin cancer	7.21e-06	0.000241	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—skin cancer	7.08e-06	0.000236	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—skin cancer	7.05e-06	0.000236	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—skin cancer	7.05e-06	0.000235	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—skin cancer	7.04e-06	0.000235	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—skin cancer	6.96e-06	0.000233	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—skin cancer	6.81e-06	0.000227	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—skin cancer	6.75e-06	0.000225	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—skin cancer	6.75e-06	0.000225	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—skin cancer	6.73e-06	0.000225	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CSPG4—skin cancer	6.53e-06	0.000218	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—skin cancer	6.44e-06	0.000215	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—skin cancer	6.28e-06	0.00021	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—skin cancer	6.04e-06	0.000202	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—skin cancer	5.87e-06	0.000196	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—skin cancer	5.81e-06	0.000194	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—skin cancer	5.78e-06	0.000193	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ERCC2—skin cancer	5.55e-06	0.000185	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—skin cancer	5.54e-06	0.000185	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—skin cancer	5.42e-06	0.000181	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—skin cancer	5.34e-06	0.000178	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—skin cancer	5.16e-06	0.000172	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—skin cancer	5.11e-06	0.000171	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—skin cancer	5.11e-06	0.000171	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—skin cancer	5.05e-06	0.000169	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—skin cancer	5.01e-06	0.000168	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—skin cancer	4.94e-06	0.000165	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—skin cancer	4.72e-06	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—skin cancer	4.66e-06	0.000156	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—skin cancer	4.6e-06	0.000154	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—skin cancer	4.44e-06	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—skin cancer	4.4e-06	0.000147	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—skin cancer	4.29e-06	0.000143	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ERCC2—skin cancer	4.19e-06	0.00014	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—skin cancer	4.11e-06	0.000137	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—skin cancer	3.96e-06	0.000132	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—skin cancer	3.91e-06	0.000131	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—skin cancer	3.79e-06	0.000127	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—skin cancer	3.79e-06	0.000127	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—skin cancer	3.74e-06	0.000125	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—skin cancer	3.58e-06	0.00012	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—skin cancer	3.33e-06	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—skin cancer	3.27e-06	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—skin cancer	2.9e-06	9.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—skin cancer	2.78e-06	9.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—skin cancer	2.66e-06	8.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ERCC2—skin cancer	2.58e-06	8.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—skin cancer	2.51e-06	8.39e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—skin cancer	1.55e-06	5.17e-05	CbGpPWpGaD
